Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

Summary

As the HGT-HIT-046 (NCT01506141) and SHP609-302 (NCT02412787) studies are completed and closed, this post-trial access (PTA) program provides TAK-609 to participants in these studies for whom the benefit:risk ratio of continued treatment with idursulfase-IT remains positive.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications